MLS Bio Announces Appointment of Innovation Leader Sergio Duchini to Board of MLS Bio (Formally Esfam Biotech)

‍1 June 2022 – Melbourne, Australia – MLS Bio is pleased to announce that Mr. Sergio Duchini has joined its Board of Directors, effective 1 June 2022.

Mr. Duchini is a seasoned executive and innovation strategist with a strong track record in translating scientific and technological opportunity into commercial impact. He has held leadership roles in industry innovation at PwC, advising on science-based transformation and guiding clients through competitive R&D strategies. He has also been actively involved with AusBiotech, contributing to Australia’s biotechnology sector through advocacy, networking, and leadership.

His expertise in innovation, coupled with deep experience in corporate governance and strategic development, will be an invaluable addition to MLS Bio. As the company advances its oncology and infectious disease pipeline, Mr. Duchini’s experience in bridging industry, science, and commercial execution will strengthen the Board’s capacity to guide this phase of growth.

“Bringing Sergio on to the Board enhances MLS Bio’s strategic depth in innovation and science translation,” said Professor Frauman, Founding Director of MLS Bio. “His insights from industry transformation, as well as his work within the biotech ecosystem via AusBiotech, align strongly with our ambition to deliver meaningful therapies on a global scale.”

Mr. Duchini commented:

“I am excited to join the Board of MLS Bio at such a pivotal moment. The company’s scientific platform holds considerable promise, and I look forward to leveraging my experience in innovation, strategy, and industry networks to help accelerate the translation of its discoveries into patient impact.”

The Board extends a warm welcome to Mr. Duchini and looks forward to his contributions to MLS Bio’s mission and long-term value creation.